{"nctId":"NCT02604810","briefTitle":"Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency","startDateStruct":{"date":"2016-01","type":"ACTUAL"},"conditions":["Primary Immunodeficiency"],"count":53,"armGroups":[{"label":"IGIV-C 10%","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IGIV-C 10%"]},{"label":"IGSC 20%","type":"EXPERIMENTAL","interventionNames":["Biological: IGSC 20%"]}],"interventions":[{"name":"IGIV-C 10%","otherNames":["Immune Globulin Injection 10% Caprylate/Chromatography"]},{"name":"IGSC 20%","otherNames":["Immune Globulin Subcutaneous 20% Caprylate/Chromatography"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pre-existing diagnosis of primary immunodeficiency with features of hypogammaglobulinemia requiring IgG replacement therapy\n* No serious bacterial infection within the last 3 months prior to or during Screening\n* Currently on IgG replacement therapy (via IV or SC infusion) for ≥3 consecutive months. Subjects receiving IGIV must be receiving a dosage of 300 to 800 mg/kg per infusion\n* Documented (at least once within previous 3 months) IgG trough level of ≥500 mg/dL on current IgG replacement therapy regimen\n\nExclusion Criteria:\n\n* Known serious adverse reaction to immunoglobulin or any severe anaphylactic reaction to blood or any blood-derived product\n* History of blistering skin disease, clinically significant thrombocytopenia, bleeding disorder, diffuse rash, recurrent skin infections, or other disorders where SC therapy would be contraindicated during the study\n* Isolated IgG subclass deficiency, isolated specific antibody deficiency disorder, or transient hypogammaglobulinemia of infancy\n* Nephrotic syndrome, and/or a history of acute renal failure and/or severe renal impairment, and/or on dialysis\n* History (year prior to Screening or 2 episodes in lifetime ) of or current diagnosis of deep venous thrombosis or thromboembolism (eg, deep vein thrombosis, myocardial infarction, cerebrovascular accident or transient ischemic attack)\n* Acquired medical condition known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (absolute neutrophil count less than 1000/μL \\[1.0 x 10\\^9/L\\]), or human immunodeficiency virus infection/acquired immune deficiency syndrome\n* Known previous infection with or clinical signs and symptoms consistent with current hepatitis B virus or hepatitis C virus infection\n* Non-controlled arterial hypertension (systolic blood pressure \\>160 mmHg and/or diastolic blood pressure \\>100 mmHg in adult subjects)\n* Receiving any of the following medications: (a) immunosuppressants including chemotherapeutic agents, (b) immunomodulators, (c) long-term systemic corticosteroids defined as daily dose \\>1 mg of prednisone equivalent/kg/day for\\>30 days Note: Intermittent courses of corticosteroids of not more than 10 days would not exclude a subject. Inhaled or topical corticosteroids are allowed.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"AUC in the IV Phase and SC Phases: Steady-state AUC of Total IgG Over a Regular Dosing Interval","description":"The primary PK endpoint (steady-state AUC values) analysis was performed using analysis of variance (ANOVA) using PK data from a total of 49 subjects from the IV phase and 39 subjects from the SC phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"207921.5","spread":null},{"groupId":"OG001","value":"213141.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Steady-state Trough (Pre-dose) Concentration of Total IgG Following IV Administration of IGIV-C 10% or SC Administration of IGSC 20%","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"957.13","spread":null},{"groupId":"OG001","value":"1244.84","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":52},"commonTop":["Sinusitis","Infusion site nodule","Bronchitis","Upper respiratory tract infection","Cough"]}}}